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Abstract Hyperuricemia and gout are common complica-
tions in adult renal transplant recipients. In pediatric
recipients, however, hyperuricemia seems to be rare, but
data are scarce. Thirty-two children (21 males, 11 females)
were investigated for a median time of 4.8 years (range:
0.4–11.2 years) following renal transplantation. The median
age of this pediatric study group was 13.9 years (range:
5.7–20.3 years), and the calculated glomerular filtration rate
(GFR) was 61 ml/min per 1.73 m2 (range:12–88 ml/min per
1.73 m2). All patients were given calcineurin inhibitors,
with 22 and ten children receiving cyclosporine A (CSA)
and tacrolimus (TAC), respectively. The median plasma
uric acid was 385 μmol/l (range: 62–929 μmol/l); 15
children (47%) were above the age-related normal range.
Only one patient experienced gouty arthritis. There was a
significant correlation between plasma uric acid concentra-
tion and both time span after transplantation and plasma
creatinine, and an inverse correlation to GFR (p<0.05). No
significant correlation was found between plasma uric acid
and body mass index (BMI). Plasma uric acid concen-
trations were neither different among CSA- and TAC-
treated children, nor did they correlate with drug exposure
or blood trough levels of CSA or TAC. Plasma uric acid
concentration was not different when compared to children
with chronic renal failure (CRF) of a similar degree in
native kidneys. We conclude that hyperuricemia is common
among pediatric renal transplant recipients and rather a
consequence of chronic renal transplant dysfunction than
the use of calcineurin inhibitors. Gout, however, is rare.
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Introduction
Hyperuricemia and gout are frequently observed among adult
renal transplant recipients, with incidence rates of up to 80
and 10%, respectively [1, 2]. Post-transplant hyperuricemia
in adults is often associated with the use of cyclosporine A
(CSA) [1, 2]. Hyperuricemia is also frequent in non-renal
organ transplant recipients, with the incidence rates ranging
from 14 to 50% in liver transplant recipients [3] and up to
30% in heart transplant recipients [4].
Uric acid is the final product of the purine metabolic
pathway originating either from endogenous or alimentary
sources. As primates lack the hepatic enzyme uricase, uric
acid in humans is mainly excreted via the renal pathway.
The main handling of renal elimination of uric acid, either
by reabsorption or secretion, takes place in the proximal
tubule [5, 6]. During childhood, hyperuricemia is uncom-
mon as children have an increased fractional excretion rate
of uric acid [6]. Hyperuricemia is mostly associated with
primary metabolic disorders of purine metabolism or tumor
lysis syndrome. In addition, several reports have shown a
correlation between plasma uric acid concentration and body
mass index (BMI) in adolescents [7, 8].
Data on hyperuricemia and gout among pediatric kidney
transplant recipients are rare. Hoyer et al. [9] described an
increased net tubular absorption of uric acid in 28 CSA-
treated pediatric renal transplant recipients. A retrospective
study from Edvardsson et al. [5] revealed hyperuricemia in
23% of children on CSA 30 months following renal
transplantation. There is only one report describing gout
in five adolescent kidney transplant recipients [10]. To date,
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no study on Tacrolimus (TAC) and hyperuricemia among
pediatric kidney transplant recipients has been published.
A case of hyperuricemia and gouty arthritis in an
adolescent renal transplant recipient prompted this retro-
spective study. Our aim was to evaluate the prevalence and
confounding clinical variables of hyperuricemia and gout in
a group of 32 pediatric kidney transplant recipients. We
hypothesized that baseline immunosuppression with either
CSA or TAC had a differential effect on plasma uric acid
levels.
Materials and methods
Thirty-two children and adolescents (21 males, 11 females)
were evaluated in a retrospective single-center study. The
median age of the children was 13.9 years (range: 5.7–
20.3 years); only two patients were older than 18 years. The
median time of the study after renal transplantation was
4.8 years (range: 0.4–11.2 years). All patients were given
calcineurin inhibitors, with 22 and ten patients on CSA and
TAC, respectively. In addition, 31 children were either on
azathioprine (n=16) or mycophenolate mofetil (n=15); nine
patients were on a steroid-free regimen, and 23 were on
low-dose alternate-day prednisone. The following factors
potentially predisposing to hyperuricemia and gout were
studied: plasma creatinine and urea, glomerular filtration
rate (GFR) as assessed by the Schwartz formula [11],
dosing (mg/m2 body surface area) and blood trough level of
CSA and TAC, use of diuretics, time after renal transplan-
tation, casual blood pressure measurement (BP) and BMI
(based on Swiss reference data [12]). The measurement of
uric acid plasma concentration by the uricase endpoint
method is part of the routine laboratory assessment.
Hyperuricemia was defined as a plasma uric acid concen-
tration above the normal range for age and sex: for children
between 2 and 15 years: 111–353 μmol/l; >15 years for
girls: 143–339 μmol/l; >15 years for boys: 202–416 μmol/l.
Plasma creatinine and CSA and TAC trough levels were
measured by the Jaffé reaction, the fluoresence polarization
immunoassay and the microbead enzyme immunoassay
(MEIA), respectively.
All patients initially received triple immunosuppressive
therapy: (1) CSA (aiming at a trough level of 180–250 μg/l
for the first 6 months and 80–120 μg/l thereafter) or TAC
(aiming at trough level of 6–10 μg/l for the first 6 months
and 4–7 μg/l thereafter); (2) azathioprine (1 mg/kg per day)
or mycophenolate mofetile (1200 and 800 mg/m2 body
surface area per day in combination with CSA or TAC,
respectively); (3) prednisone (initially 1 mg/kg daily with
rapid tapering and a switch to alternate days after 6 months).
The antihypertensive drug of choice was a calcium-channel
blocker (nifedipine). If additional antihypertensive treat-
ment were necessary, a beta-blocker (atenolol), angiotensin-
converting enzyme (ACE)-inhibitor (enalapril) or diuretic
(furosemide) was administered.
Beyond the first year after transplantation, patients were
followed in the renal transplant clinic once every month.
The statistical calculations (i.e. GFR and correlations) were
based on a single measurement. The measured parameters,
however, did not show any significant variation during
three consecutive consultations (data not shown), with the
exception of a single patient suffering from gout.
GFR and plasma uric acid concentration were also
measured in a group of 23 patients (seven females, 16
males) with chronic renal failure (CRF) of their native
kidneys (median age: 12.9 years; range: 4.8–19.7 years).
Statistical analysis was performed using a Pearson
correlation coefficient and the Mann-Whitney-test for
comparison of parametric variables between groups. Statis-
tical significance was assigned to p<0.05.
Results
Median plasma uric acid concentration was 385 μmol/l
(range: 62–929 μmol/l). Fifteen children (47%) had hyper-
uricemia with uric acid concentrations above the age-related
normal range; 12 (out of 22; 55%) were on CSA and three
(out of 10; 30%) were on TAC. Median plasma creatinine
was 102 μmol/l (range: 53–482 μmol/l), with a median
calculated GFR of 61 ml/min per 1.73 m2 (range: 12–88 ml/
min per 1.73 m2). There was a significant correlation
between plasma uric acid concentration and the time span
after renal transplantation (p<0.05; Fig. 1). There was also a
significant correlation between plasma uric acid concentra-
tion and plasma creatinine (data not shown) and an inverse
correlation with GFR (p<0.05; Fig. 2). However, plasma uric
acid concentrations did not differ among patients with CSA
or TAC therapy (mean±SD: 402±114 vs. 332±114; p=n.s.).
In addition, no significant correlation was found between
plasma uric acid concentration and both CSA and TAC dose
or blood trough level. The mean daily dose of TAC and CSA
was 5.15 (±SD: 2.19) and 129 mg/m2 (±34.03), respectively,
and the mean whole blood trough level was 6.9 (±2.09) and
109 μg/l (±28.9 μg/l), respectively. All except two patients
(SDS: −2.52 and +3.61) had a BMI within the normal age-
related range [12]. There was no significant correlation
between BMI (SDS) and plasma uric acid concentration. All
patients had a casual blood pressure <95 percentile, with
three adolescent boys on antihypertensive treatment: two
were on atenolol and/or nifedipine, and one was also on
furosemide.
The latter – a 15-year-old boy with sporadic steroid-
resistant focal segmental sclerosis – was the only patient
suffering from clinical gout. The first gouty episode
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occurred 7.9 years after renal transplantation and man-
ifested as arthritis of the metatarso-phalangeal joint of the
left big toe. The maximal plasma uric acid concentration
was 929 μmol/l, with moderate CRF (plasma creatinine:
214 μmol/l) due to chronic transplant nephropathy. Immuno-
suppression consisted of CSA (trough levels: 95–158 μg/l),
azathioprine and alternate-day prednisone; this patient was
the only one in this series on diuretics. Since receiving
allopurinol over the long term, he has been free of gouty
symptoms.
A control group of 23 patients with CRF of their native
kidneys and a median GFR of 58 ml/min per 1.73 m2
(range: 24–94 ml/min per 1.73 m2) had a median uric acid
concentration of 368 μmol/l (range: 173–561 μmol/l).
None of these patients received diuretics. The GFR and
uric acid concentration were not significantly different from
those of children who had received a kidney transplant.
Discussion
This report demonstrates that not only adult patients can
suffer from hyperuricemia: among our study cohort also
one-half of the pediatric renal transplant recipients were
also found to have hyperuricemia. However, in contrast to
adult patients, gout was rare. Interestingly, hyperuricemia in
our series was not correlated to calcineurin inhibition, and
the incidence rate was not different between CSA- or TAC-
treated patients but, rather, it was correlated to chronic renal
graft dysfunction. Consistent with the paucity of cases
among pediatric renal transplant recipients [10], gout
occurred in only one patient.
A previous pediatric study by Edvardsson showed a
peak uric acid concentration in the patients at 6 months
after transplantation, when 39% of the patients had
hyperuricemia and 60% were receiving diuretics. At
30 months, significantly fewer patients had hyperuricemia
(23%) or were on diuretics (17%) [5]. Our study differed
from that of Edvardsson on a number of points: (1) our
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Fig. 1 Correlation between
plasma uric acid concentration
and the time span after renal
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patients were studied after a median period of almost
5 years following the transplantation; (2) the calculated
GFR was lower; (3) only one patient was on diuretics; (4)
one-third of the patients were on TAC. Consistent with
previous studies, impaired renal function – i.e. chronic
transplant nephropathy – was the most important factor
contributing to hyperuricemia [5, 9, 13, 14]. The fact that
our control patients showed no difference in plasma uric
acid concentration from our transplant patients when there
was a similar degree of CRF in the native kidneys supports
this notion.
CSA contributes to hyperuricemia and gout among adult
renal transplant recipients [1, 2] and does this by two
different mechanisms: (1) by increased proximal uric acid
reabsorption, especially in the presence of volume depletion
associated with diuretic use [9, 13]; (2) by a decrease in
GFR secondary to afferent arteriolar vasoconstriction [15].
Both effects are not limited to renal transplantation as
hyperuricemia and gout are also frequent in CSA-treated
adults receiving non-renal solid organs, i.e. the liver [3] or
heart [4]. On the other hand, Braun et al. reported a high
incidence of gout among renal transplant patients treated
solely with azathioprine and prednisone [16]. In pediatric
renal transplantation, the hyperuricemic effect of CSA
appears to be less significant. Our study did not find any
correlation between calcineurin inhibition, measured as
either a daily dosage or blood trough level, and plasma
uric acid concentration. This result is consistent with that of
a previous study [5]. The results of two different studies by
Laine et al. [17] and Hoyer et al. [9], respectively,
suggested that CSA may lead to hyperuricemia in pediatric
renal recipients. These researchers based this proposal on
the observation that the renal handling of uric acid
demonstrated an increased net tubular reabsorption.
TAC is a calcineurin inhibitor with similar properties and
adverse effects as CSA, including nephrotoxicity, hyper-
tension and hyperuricemia; however, it may cause gout to a
lesser extent than CSA [18–20]. Kanbay et al. recently
reported on the influence of CSA- and TAC-based regimens
on serum uric acid concentration: they observed that 155
adult renal kidney transplant recipients with both CSA and
TAC increased their uric acid concentration in a similar
manner [21]. In our series, three out of ten children on TAC
had hyperuricemia; two were adolescents with a markedly
reduced GFR of 12 and 33 ml/min/1.73 m2, respectively.
Diuretics, i.e. loop diuretics, thiazides, amiloride, triam-
terene, and spironolactones, are also associated with post-
transplant hyperuricemia, both in adult [1, 22, 23] and
pediatric recipients [5]. The increase in plasma uric acid
concentration may be noted within a few days of the
initiation of treatment despite the use of low doses [24].
In our small series, we found no correlation between
patients’ BMI and plasma uric acid concentration. This is in
contrast with observations in healthy adolescents. However,
only one patient had a BMI above the age-related normal
range [12]. In addition, dietary excess (meat, seafood,
alcohol), which is a frequent risk factor for hyperuricemia
among adults, was not present [25].
Gout among pediatric renal transplant recipients is rare.
Pela et al. reported five cases of adolescents developing
gout 2–84 months after kidney transplantation; all were
receiving CSA and two were on furosemide because of
hypertension [10]. The contributing factors in the only
patient of our series with gout were chronic transplant
nephropathy and the combined use of CSA and diuretics.
The uricostatic drug allopurinol is an effective prophylaxis
for hyperuricemia and gout. However, because its mecha-
nism involves xanthine oxidase enzyme inactivation, it
interacts with azathioprine, and the dose of azathioprine has
to be reduced by approximately 50% to prevent severe bone
marrow depletion [23]. There are no reports of interactions
of allopurinol and other immunosuppressive drugs. Acute
antiphlogistic therapy with non-steroid-antiinflammatory
drugs (NSAID) has to be considered carefully as this can
lead to significant impairment of renal function in patients
with chronic transplant nephropathy. A short course of
steroids is an efficient and safe alternative.
Does hyperuricemia per se contribute to an aggravation
of chronic transplant nephropathy? A single report sug-
gested that hyperuricemia had a significantly negative
impact on renal graft survival after 5 years in adult patients,
with a survival rate of 68.8% in hyperuremic versus 83.3%
in normouremic recipients [26]. Animal models have
shown that uric acid can induce aggravation of CSA-
vasculopathy and interstitial injury [27].
In conclusion, hyperuricemia after pediatric renal trans-
plantation is common. It is correlated with the time span
after transplantation and is a consequence of chronic renal
transplant dysfunction. Gout is rare.
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